Ganglioside GD1a Antibody IgG

What the laboratory says this test is for

The panel includes ganglioside antibodies associated with motor neuropathies. Many of the anti-ganglioside antibodies associated with chronic immune neuropathies are monoclonal IgM antibodies. An evaluation for monoclonal gammopathy should be performed in this setting.

What the laboratory says this test is for

Ganglioside GM-1 IgG antibody is associated with acute inflammatory demyelinating polyneuropathy and acute motor axonal neuropathy. GD1a IgG antibody may also be associated with acute motor axonal neuropathy. GD1b IgG antibody may be associated with acute motor and sensory axonal neuropathy with cerebellar ataxia or ataxic presentations of Guillain-Barré Syndrome. GQ1b IgG antibody is associated with the Miller-Fisher Syndrome.

What the laboratory says this test is for

The presence of antibodies to the gangliosides GM1, Asialo-GM1, GD1a and GD1b has been associated with motor and sensorimotor neuropathies. High titers of antibody to GM1 are most typical of multifocal motor neuropathy; however, antibodies to other gangliosides are often present. In most cases of chronic immune neuropathies, anti-ganglioside antibodies are IgM class. IgG antibodies have been reported less often, generally associated with acute conditions. Many reports have found increased anti-asialo-GM1 antibody titers in patients with multifocal motor neuropathy, lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal block, Guillain-Barré Syndrome, and amyotrophic lateral sclerosis. There may be a relationship between titers of asialo-GM1 antibodies and clinical status in individual patients. In some lower motor neuron disorders, improvement in strength has occurred after therapeutic reduction in anti-asialo-GM1 antibody titers. Polyclonal GQ1b IgG antibody can serve as an aid in the diagnosis of acute ataxia neuropathy with ophthalmoplegia or of Miller-Fisher Syndrome.

What the laboratory says this test is for

The presence of antibodies to the gangliosides GM1, Asialo-GM1, and GD1a has been associated with motor neuropathies. High titers of antibody to GM1 are most typical of multifocal motor neuropathy; however, antibodies to other gangliosides are often present. In most cases, anti-ganglioside antibodies are IgM class. IgG antibodies have been reported less often, generally associated with acute conditions. Many reports have found increased anti-asialo-GM1 antibody titers in patients with multifocal motor neuropathy, lower motor neuron disease, or motor neuropathy with or without multifocal block, Guillain-Barré Syndrome, and amyotrophic lateral sclerosis. There may be a relationship between titers of asialo-GM1 antibodies and clinical status in individual patients. In some lower motor neuron disorders, improvement in strength has occurred after therapeutic reduction in anti-asialo-GM1 antibody titers.